CRISPR Therapeutics AG (CRSP) Income from Non-Controlling Interests (2016 - 2019)
Historic Income from Non-Controlling Interests for CRISPR Therapeutics AG (CRSP) over the last 5 years, with Q1 2019 value amounting to $14.2 million.
- CRISPR Therapeutics AG's Income from Non-Controlling Interests rose 1360.0% to $14.2 million in Q1 2019 from the same period last year, while for Mar 2019 it was $54.4 million, marking a year-over-year increase of 2592.59%. This contributed to the annual value of $52.5 million for FY2018, which is 4502.76% up from last year.
- As of Q1 2019, CRISPR Therapeutics AG's Income from Non-Controlling Interests stood at $14.2 million, which was up 1360.0% from $14.1 million recorded in Q4 2018.
- Over the past 5 years, CRISPR Therapeutics AG's Income from Non-Controlling Interests peaked at $14.2 million during Q1 2019, and registered a low of -$16000.0 during Q4 2015.
- Moreover, its 5-year median value for Income from Non-Controlling Interests was $9.0 million (2017), whereas its average is $6.9 million.
- In the last 5 years, CRISPR Therapeutics AG's Income from Non-Controlling Interests crashed by 130000.0% in 2016 and then surged by 115010000.0% in 2017.
- CRISPR Therapeutics AG's Income from Non-Controlling Interests (Quarter) stood at -$16000.0 in 2015, then skyrocketed by 93.75% to -$1000.0 in 2016, then soared by 1150100.0% to $11.5 million in 2017, then increased by 22.61% to $14.1 million in 2018, then grew by 0.71% to $14.2 million in 2019.
- Its Income from Non-Controlling Interests was $14.2 million in Q1 2019, compared to $14.1 million in Q4 2018 and $12.6 million in Q3 2018.